<DOC>
	<DOCNO>NCT00625950</DOCNO>
	<brief_summary>Dopamine agonist , quinagolide , able act VEGFR-2 blocking antibody , diminish Vascular Endothelial Growth Factor effect angiogenesis human endometriotic lesion .</brief_summary>
	<brief_title>Endometriosis Patients Undergoing Quinagolide Treatment</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Hyperprolactinemia</mesh_term>
	<criteria>Hyperprolactinemia Unexplained infertility Endometriosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Hyperprolactinemia</keyword>
	<keyword>Endometriosis</keyword>
	<keyword>laparoscopy</keyword>
	<keyword>angiogenesis , VEGF</keyword>
</DOC>